|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US6218525B1
(en)
|
1988-02-25 |
2001-04-17 |
The General Hospital Corporation |
Nucleic acid encoding CD28
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6685941B1
(en)
|
1988-11-23 |
2004-02-03 |
The Regents Of The University Of Michigan |
Methods of treating autoimmune disease via CTLA-4Ig
|
|
US6291159B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
|
US5521288A
(en)
|
1990-03-26 |
1996-05-28 |
Bristol-Myers Squibb Company |
CD28IG fusion protein
|
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
WO1992009690A2
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with altered binding properties
|
|
DE69230142T2
(de)
|
1991-05-15 |
2000-03-09 |
Cambridge Antibody Technology Ltd. |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
|
DE122004000008I1
(de)
|
1991-06-14 |
2005-06-09 |
Genentech Inc |
Humanisierter Heregulin Antikörper.
|
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US6887471B1
(en)
*
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
DE69226871T3
(de)
|
1991-06-27 |
2009-09-24 |
Bristol-Myers Squibb Co. |
CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
|
US6482919B2
(en)
|
1993-02-01 |
2002-11-19 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
EP0714409A1
(en)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5942607A
(en)
|
1993-07-26 |
1999-08-24 |
Dana-Farber Cancer Institute |
B7-2: a CTLA4/CD28 ligand
|
|
US6130316A
(en)
|
1993-07-26 |
2000-10-10 |
Dana Farber Cancer Institute |
Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
|
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
|
US6218510B1
(en)
|
1994-03-02 |
2001-04-17 |
Brigham & Woman's Hospital |
B7-1 and B7-2 polypeptides
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
EP1012275A1
(en)
|
1997-01-31 |
2000-06-28 |
University Of Rochester |
Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
US6730512B2
(en)
|
1997-04-09 |
2004-05-04 |
Amdl, Inc. |
Combination immunogene therapy
|
|
AU736707B2
(en)
|
1997-06-11 |
2001-08-02 |
Anaphore, Inc. |
Trimerising module
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
US5891432A
(en)
|
1997-07-29 |
1999-04-06 |
The Immune Response Corporation |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9823071D0
(en)
|
1998-10-21 |
1998-12-16 |
Affibody Technology Ab |
A method
|
|
KR101155191B1
(ko)
|
1999-01-15 |
2012-06-13 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
|
CA2369747A1
(en)
|
1999-04-30 |
2000-11-09 |
The Trustees Of The University Of Pennsylvania |
Mutant human cd80 and compositions for and methods of making and using the same
|
|
GB9917027D0
(en)
|
1999-07-20 |
1999-09-22 |
Affibody Technology Sweeden Ab |
In vitro selection and optional identification of polypeptides using solid support carriers
|
|
PT1218504E
(pt)
|
1999-09-21 |
2007-10-22 |
Genetics Inst Llc |
Novas moléculas gl50 e suas utilizações
|
|
AU2926401A
(en)
|
2000-01-03 |
2001-07-16 |
Tr Associates, L.L.C. |
Novel chimeric proteins and methods for using the same
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
EG24459A
(en)
|
2000-05-26 |
2009-07-16 |
Bristol Myers Squibb Co |
Soluble CTLA4 mutant molecules and uses thereof
|
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
EP1360290A2
(en)
|
2000-06-23 |
2003-11-12 |
Maxygen, Inc. |
Co-stimulatory molecules
|
|
WO2004029197A2
(en)
|
2001-06-22 |
2004-04-08 |
Maxygen, Inc. |
Co-stimulatory molecules
|
|
US7183376B2
(en)
*
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
|
AU7309601A
(en)
|
2000-06-28 |
2002-01-08 |
Genetics Inst |
Pd-l2 molecules: novel pd-1 ligands and uses therefor
|
|
RU2287340C2
(ru)
|
2000-07-03 |
2006-11-20 |
Бристол-Маерс Сквибб Компани |
Способы лечения ревматических заболеваний с применением растворимого ctla4
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
US6635750B1
(en)
|
2000-07-20 |
2003-10-21 |
Millennium Pharmaceuticals, Inc. |
B7-H2 nucleic acids, members of the B7 family
|
|
HU229680B1
(hu)
|
2001-05-23 |
2014-04-28 |
Bristol Myers Squibb Co |
Eljárások allogén sziget átültetés védelmére oldható CTLA4 mutáns molekulák alkalmazásával
|
|
JP4572276B2
(ja)
*
|
2001-06-29 |
2010-11-04 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ |
Ｔ細胞調節遺伝子およびその使用方法
|
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
|
WO2003042402A2
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
US7235631B2
(en)
|
2002-02-07 |
2007-06-26 |
Mayo Foundation For Medical Education And Research |
ICOS mutants
|
|
DK1553966T3
(da)
|
2002-10-03 |
2012-09-17 |
Wyeth Corp |
Fusionspeptider omfattende human papillomavirus E7- og E6- polypeptider samt immunogene sammensætninger deraf
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
DE60332957D1
(de)
|
2002-12-16 |
2010-07-22 |
Genentech Inc |
Immunoglobulinvarianten und deren verwendungen
|
|
TWI328614B
(en)
|
2002-12-23 |
2010-08-11 |
Bristol Myers Squibb Co |
Product quality enhancement in mammalian cell culture processes for protein production
|
|
EP1591527B1
(en)
|
2003-01-23 |
2015-08-26 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human pd-1
|
|
WO2005016266A2
(en)
|
2003-08-04 |
2005-02-24 |
Bristol-Myers Squibb Company |
Methods for treating cardiovascular disease using a soluble ctla4 molecule
|
|
WO2005074546A2
(en)
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Modified human growth hormone polypeptides and their uses
|
|
PL1737891T3
(pl)
|
2004-04-13 |
2013-08-30 |
Hoffmann La Roche |
Przeciwciała przeciw selektynie p
|
|
EP2940043A1
(en)
|
2004-07-15 |
2015-11-04 |
Xencor, Inc. |
Optimized fc variants
|
|
JP2008507280A
(ja)
|
2004-07-21 |
2008-03-13 |
アンブレツクス・インコーポレイテツド |
非天然コードアミノ酸を用いた生合成ポリペプチド
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
EP1824878A1
(en)
|
2004-11-22 |
2007-08-29 |
Borean Pharma A/S |
Tnf antagonists
|
|
CA2590590C
(en)
|
2004-12-22 |
2016-04-19 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
PT1868635T
(pt)
|
2005-04-06 |
2017-07-27 |
Bristol Myers Squibb Co |
Métodos para tratar distúrbios imunes associados a transplantação de enxerto com moléculas mutantes solúveis de ctla4
|
|
HRP20110404T1
(hr)
|
2005-11-08 |
2011-08-31 |
Ambrx |
Ubrzivači za modifikaciju ne-prirodnih aminokiselina i polipeptida ne-prirodnih aminokiselina
|
|
ES2439641T3
(es)
|
2005-12-20 |
2014-01-24 |
Bristol-Myers Squibb Company |
Composiciones y procedimientos de producción de una composición
|
|
CN104193815A
(zh)
|
2006-09-08 |
2014-12-10 |
Ambrx公司 |
经修饰的人类血浆多肽或Fc骨架和其用途
|
|
GB0620934D0
(en)
|
2006-10-20 |
2006-11-29 |
Cambridge Antibody Tech |
Protein variants
|
|
US8907065B2
(en)
|
2006-12-15 |
2014-12-09 |
Ablynx N.V. |
Polypeptides that modulate the interaction between cells of the immune system
|
|
JP5840837B2
(ja)
|
2007-03-30 |
2016-01-06 |
メモリアル スローン−ケタリング キャンサー センター |
養子移入ｔリンパ球における副刺激リガンドの構成性発現
|
|
NZ580686A
(en)
|
2007-05-02 |
2012-11-30 |
Ambrx Inc |
Modified interferon beta polypeptides and their uses
|
|
CA2693707A1
(en)
|
2007-07-13 |
2009-03-05 |
The Johns Hopkins University |
B7-dc variants
|
|
AU2008319053B2
(en)
|
2007-11-01 |
2012-04-26 |
Astellas Pharma Inc. |
Immunosuppressive polypeptides and nucleic acids
|
|
CA2713872A1
(en)
|
2008-02-21 |
2009-08-27 |
Burnham Institute For Medical Research |
Methods and compositions related to peptides and proteins with c-terminal elements
|
|
WO2009117622A2
(en)
|
2008-03-19 |
2009-09-24 |
Ambrx, Inc. |
Modified fgf-23 polypeptides and their uses
|
|
CN102057272B
(zh)
|
2008-04-09 |
2015-02-18 |
健泰科生物技术公司 |
用于免疫相关疾病的治疗的新组合物和方法
|
|
US7915222B2
(en)
|
2008-05-05 |
2011-03-29 |
Bristol-Myers Squibb Company |
Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
|
|
US9593376B2
(en)
|
2008-06-02 |
2017-03-14 |
Institut Gustave Roussy |
Natural killer p30 (NKp30) dysfunction and the biological applications thereof
|
|
US9931386B2
(en)
|
2008-06-16 |
2018-04-03 |
Atsuo Ochi |
Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
|
|
AU2009274076C1
(en)
|
2008-07-23 |
2014-04-17 |
Ambrx, Inc. |
Modified bovine G-CSF polypeptides and their uses
|
|
CN102203132A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂的组合物和使用方法
|
|
CN102203125A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂及其使用方法
|
|
PL2342223T3
(pl)
|
2008-09-26 |
2017-09-29 |
Ambrx, Inc. |
Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
|
|
JP5943608B2
(ja)
|
2009-02-04 |
2016-07-05 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
心臓障害の治療におけるｍｉｒ−２０８およびｍｉｒ−４９９の二重ターゲティング
|
|
US8840889B2
(en)
*
|
2009-08-13 |
2014-09-23 |
The Johns Hopkins University |
Methods of modulating immune function
|
|
PL2482849T3
(pl)
|
2009-09-30 |
2018-11-30 |
Memorial Sloan-Kettering Cancer Center |
Skojarzona immunoterapia w leczeniu nowotworu
|
|
US9540426B2
(en)
|
2009-10-06 |
2017-01-10 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
|
JP2013512251A
(ja)
|
2009-11-24 |
2013-04-11 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
|
|
EP2531216B1
(en)
|
2010-02-04 |
2019-03-27 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
|
LT2536745T
(lt)
|
2010-02-19 |
2016-09-26 |
Xencor, Inc. |
Nauji ctla4-ig imunoadhezinai
|
|
IL323000A
(en)
|
2010-03-05 |
2025-10-01 |
Univ Johns Hopkins |
Compositions and methods for antibodies and fusion proteins targeted for immune modulation
|
|
EP2545073B1
(en)
*
|
2010-03-12 |
2015-09-30 |
AbbVie Biotherapeutics Inc. |
Ctla4 proteins and their uses
|
|
WO2012062218A1
(en)
*
|
2010-11-11 |
2012-05-18 |
The University Of Hong Kong |
Soluble pd-1 variants, fusion constructs, and uses thereof
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
SI2697257T1
(sl)
|
2011-04-13 |
2017-02-28 |
Bristol-Myers Squibb Company |
FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve
|
|
RU2623161C2
(ru)
|
2011-04-15 |
2017-06-22 |
Компуджен Лтд. |
Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
|
|
CN102836441B
(zh)
|
2011-06-24 |
2019-06-11 |
台北荣民总医院 |
于感染性与恶性疾病的治疗中提升免疫反应的方法
|
|
PT2726101T
(pt)
|
2011-06-30 |
2018-11-21 |
Genzyme Corp |
Inibidores da ativação de células t
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
RS61033B1
(sr)
|
2011-11-28 |
2020-12-31 |
Merck Patent Gmbh |
Antitela na pd-l1 i njihova upotreba
|
|
KR102057356B1
(ko)
|
2012-02-27 |
2019-12-18 |
아뮤닉스 파마슈티컬스, 인크. |
Ｘｔｅｎ 콘주게이트 조성물 및 그의 제조 방법
|
|
WO2013148049A1
(en)
|
2012-03-29 |
2013-10-03 |
The General Hospital Corporation |
Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
|
|
DK3207938T3
(da)
|
2012-05-11 |
2020-03-16 |
Medimmune Ltd |
Ctla-4-varianter
|
|
HK1204950A1
(en)
|
2012-06-06 |
2015-12-11 |
昂考梅德药品有限公司 |
Binding agents that modulate the hippo pathway and uses thereof
|
|
CN113138279A
(zh)
|
2012-06-27 |
2021-07-20 |
法姆制药有限责任公司 |
融合蛋白组合物的应用
|
|
JP5857896B2
(ja)
|
2012-07-06 |
2016-02-10 |
東京エレクトロン株式会社 |
成膜装置の運転方法及び成膜装置
|
|
AU2013355379B2
(en)
|
2012-12-04 |
2018-08-09 |
Oncomed Pharmaceuticals, Inc. |
Immunotherapy with binding agents
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
US9944689B2
(en)
|
2013-03-07 |
2018-04-17 |
The General Hospital Corporation |
Human CTLA4 mutants and use thereof
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
US20160271218A1
(en)
|
2013-06-27 |
2016-09-22 |
Mor Research Applications Ltd. |
Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
|
|
MX384142B
(es)
|
2013-07-16 |
2025-03-14 |
Genentech Inc |
Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
|
|
CN105916883B
(zh)
|
2014-01-28 |
2019-12-03 |
北京韩美药品有限公司 |
双功能融合蛋白及其制备方法和用途
|
|
ES2792849T3
(es)
|
2014-02-10 |
2020-11-12 |
Univ Emory |
Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
|
|
KR20160145789A
(ko)
|
2014-04-25 |
2016-12-20 |
브리스톨-마이어스 스큅 컴퍼니 |
초기 ra를 갖는 대상체에서의 무약물 완화를 달성하기 위한 ctla4 화합물의 용도
|
|
CN120555373A
(zh)
|
2014-07-16 |
2025-08-29 |
特兰斯吉恩股份有限公司 |
用于表达免疫检查点调节因子的溶瘤病毒
|
|
AU2015289621A1
(en)
|
2014-07-16 |
2017-01-12 |
Genentech, Inc. |
Methods of treating cancer using TIGIT inhibitors and anti-cancer agents
|
|
ES2819451T3
(es)
|
2014-08-08 |
2021-04-16 |
Univ Leland Stanford Junior |
Agentes PD-1 de alta afinidad y procedimientos de uso
|
|
WO2016034678A2
(en)
|
2014-09-03 |
2016-03-10 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
|
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
|
CA2966988A1
(en)
|
2014-11-06 |
2016-05-12 |
Children's Research Institute, Children's National Medical Center |
Immunotherapeutics for cancer and autoimmune diseases
|
|
WO2016118577A1
(en)
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
EP3277313B1
(en)
|
2015-04-02 |
2021-06-23 |
Cancure Limited |
Agents and compositions for eliciting an immune response
|
|
WO2016164428A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
|
|
EP3875477A1
(en)
|
2015-04-17 |
2021-09-08 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
JP6797137B2
(ja)
|
2015-05-29 |
2020-12-09 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｏｘ４０に対する抗体およびその使用
|
|
SMT202100527T1
(it)
|
2015-07-30 |
2021-11-12 |
Macrogenics Inc |
Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
|
|
CA2993429A1
(en)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
|
WO2017023749A1
(en)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immunomodulation
|
|
US10632174B2
(en)
|
2015-08-20 |
2020-04-28 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V |
B7-H1 fusion polypeptides for treating and preventing organ failure
|
|
BR112018004965A2
(pt)
|
2015-09-14 |
2018-10-09 |
Alpine Immune Sciences Inc |
domínios de superfamìlia de imunoglobulina variante ajustàvel
|
|
SG10201912943RA
(en)
|
2015-10-02 |
2020-02-27 |
Symphogen As |
Anti-pd-1 antibodies and compositions
|
|
BR112018008865A8
(pt)
|
2015-11-02 |
2019-02-26 |
Five Prime Therapeutics Inc |
polipeptídeos do domínio extracelular cd80 e seu uso no tratamento do câncer
|
|
JP7148399B2
(ja)
|
2015-11-04 |
2022-10-05 |
タイペイ・ベテランズ・ジェネラル・ホスピタル |
悪性疾患に対する併用療法
|
|
SG11201804839WA
(en)
|
2015-12-14 |
2018-07-30 |
Macrogenics Inc |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
|
US20190062400A1
(en)
|
2016-03-02 |
2019-02-28 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
CA3019199A1
(en)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Icos ligand variant immunomodulatory proteins and uses thereof
|
|
AU2017248830B2
(en)
|
2016-04-15 |
2023-03-09 |
Alpine Immune Sciences, Inc. |
CD80 variant immunomodulatory proteins and uses thereof
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
SG11201903302UA
(en)
|
2016-10-14 |
2019-05-30 |
Xencor Inc |
Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
|
|
AU2017345764A1
(en)
|
2016-10-20 |
2019-05-02 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
CA3053812A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Pd-l2 variant immunomodulatory proteins and uses thereof
|
|
IL320149A
(en)
|
2017-03-16 |
2025-06-01 |
Alpine Immune Sciences Inc |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
|
IL319966A
(en)
|
2017-03-16 |
2025-05-01 |
Alpine Immune Sciences Inc |
CD80 Variant Immune Modulator Proteins and Uses Thereof
|
|
KR102813968B1
(ko)
|
2017-10-10 |
2025-05-29 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
|
TW202500579A
(zh)
|
2017-10-18 |
2025-01-01 |
美商艾爾潘免疫科學有限公司 |
變異型icos 配位體免疫調節蛋白及相關組合物及方法
|
|
US12297253B2
(en)
|
2018-01-03 |
2025-05-13 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
US20220177587A1
(en)
|
2018-09-19 |
2022-06-09 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant cd80 fusion proteins and related constructs
|
|
WO2021181233A2
(en)
|
2020-03-09 |
2021-09-16 |
Pfizer Inc. |
Fusion proteins and uses thereof
|
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|